The company's second quarter revenue growth was driven in part by strong sales from its life science segment.
The company has aspirations for a combined molecular/immunoassay platform, but plans to go to market with a 22-target real-time PCR-enabled syndromic panel.
The Alabama-based firm has grown its infectious disease testing menu for the BD Max system to six CE-marked tests identifying bacteria, viruses, or fungi.
The companies will work together to secure US approval for SpeeDx's antibiotic-resistant Mycoplasma genitalium assay.
The new panel is able to detect up to 130 pathogens that cause severe abdominal infections, such as appendicitis and acute pancreatitis.
The Chan Zuckerberg Initiative is investing in Cold Spring Harbor Laboratory's BioRxiv.
A study appearing in PLOS One finds that shortened consent forms don't affect clinical trial participants' understanding of the study.
The National Security Agency monitored signal intelligence for signs of "nefarious" genetic engineering projects, Gizmodo reports.
In Nature this week: barley genome sequenced, method for genotyping and phasing short tandem repeats, and more.